Aggregate Report Management: From Complex Data to Clear Safety Insights
Turning Safety Data into Clear, Trusted Reporting
Pharmaceutical companies and healthcare innovators today face growing expectations to deliver timely, compliant and meaningful aggregate safety reports across global markets and expanding product portfolios. At APCER, we understand that robust aggregate report management is not only a regulatory requirement. It is a critical pillar of patient safety and trust in healthcare.
APCER is your partner in delivering clarity and confidence in aggregate report management. Our centralized team of healthcare professionals, of which over 30% are physicians, manage the full spectrum of aggregate reports across therapeutic areas and product portfolios. With structured workflows, deep scientific expertise and a collaborative approach, we ensure every report is delivered with precision, quality and regulatory integrity.
Why Leading Life Sciences Companies Trust APCER for Aggregate Report Management
Delivering aggregate safety reports demands more than regulatory knowledge. It requires clinical insight, structured processes, and a deep understanding of global expectations. At APCER, our teams bring the expertise, scale, and discipline needed to deliver reports that regulators trust and patients depend on.
- Expert Clinical Team 50+ dedicated specialists with strong clinical expertise, of which over 30% are physicians
- 750+ Reports Annually Over 750 aggregate reports delivered annually for over 40 global life sciences companies
- Comprehensive Report Expertise Extensive experience across various types of aggregate reports, including Periodic Safety Update Report (PSUR) and Periodic Benefit-Risk Evaluation Report (PBRER), Development Safety Update Report (DSUR), Periodic Adverse Drug Experience Report (PADER), Addendum to Clinical Overview (ADCO), Clinical Expert Statement (CES), Summary Bridging Report (SBR), Annual Safety Report (ASR), addendum report, and other global report types
- Regulatory Compliance Support Robust documentation practices and proactive regulatory readiness supporting confident compliance.
Aggregate Report Management in Action
A global MedTech company stabilized PSUR operations and strengthened EU MDR compliance through APCER's aggregate reporting expertise.
Our Impact at a Glance
Our Aggregate Report Management Capabilities at a Glance
APCER brings together clinical insight, regulatory expertise, and proven delivery processes to support life sciences companies in managing aggregate safety reporting with confidence across diverse products and global market
Comprehensive Report Coverage
Comprehensive Report Coverage
PSUR and PBRER, DSUR, PADER, ADCO, CES, SBR, ASR, addendum reports and other global report types
Complete Lifecycle Support
Complete Lifecycle Support
From line listing generation and data analysis to submission and regulatory follow up
Cross Portfolio Expertise
Cross Portfolio Expertise
Supporting innovator products, generics, medical devices, and drug device combinations
Centralized Expert Team
Centralized Expert Team
More than 50 specialists including over 30 percent physicians
Proven Delivery at Scale
Proven Delivery at Scale
750+ reports delivered each year for over 40 global clients
Ready for a partner who matches your ambition?
With APCER, you gain more than a service provider—you secure a champion for compliance, a catalyst for growth, and a steadfast ally dedicated to protecting patients and your reputation.
Quality and Compliance
- Version-controlled SOPs
- Role-based structured training
- End-to-end Deviation and CAPA lifecycle management
- Risk-based audit program
- electronic Quality Management System (eQMS) and electronic Learning Management System (eLMS)
Real Results. Real Trust.
Real Stories
Sincerely thank you for all the effort, thoroughness and professionalism that went through conducting and reporting on this FDA PADER Gap Analysis as we now embark on our journey towards documentation and process improvement to ensure readiness for an actual inspection.
Director, Drug Safety and Medical Information
Canada-based global pharma
The APCER Pharmacovigilance team demonstrated exceptional collaboration and inspection readiness during FDA PADE Inspection. The accuracy, consistency, and completeness of expedited reports, reconciliations, and aggregate safety documentation clearly reflected strong teamwork and compliance across all deliverables.
VP, Regulatory and Quality
US-based biopharma
With all the transformation and rapid growth happening, having a reliable PV/med info partner like the APCER group has truly been invaluable—it’s made a real difference in helping us navigate the complexities and keep challenges to a minimum.
VP, Medical Affairs
US-based specialty pharma
... the preparation and support for our BPD Type 2a meeting were a strong example of APCER’s commitment and effectiveness and instrumental in keeping us aligned and confident in our regulatory strategy. We have greatly valued the team’s responsiveness, collaborative approach, and sound regulatory judgment.
Chief Medical Officer
A clinical-stage biopharma
Phase 1 completion is an achievement that demonstrates APCER's scalability, flexibility, and operational readiness. It reflects exceptional cross-functional collaboration.
Associate Director, IT Business Partner
Japan-headquartered, global healthcare company
I want to sincerely appreciate all the great work Team APCER has been doing. Their strong attention to detail, agility in handling tasks, and consistent respect for timelines have been truly impressive.
Associate Director, Safety Physician
Japan-headquartered, global healthcare company
Deep gratitude to entire APCER team for their efforts in working hard to complete the cases. While the system outage was well beyond their control, their strong work to make up for the lost time ensured that we're able to maintain compliance.
Associate Director, Pharmacovigilance Operations
US-based biotech
Sincere appreciation for APCER's partnership and dedicated service. The team’s commitment, adaptability, and collaborative approach have been instrumental in supporting our pharmacovigilance operations through both high and low volumes of activity.
Sr.Director, PV Operations-Global Case Management
US-based biotech
I’ve greatly valued APCER’s commitment to excellence. Their contributions have played a key role in helping us uphold our compliance standards and achieve strong performance across key metrics, including timely deviation closure, audit readiness, and quality of deliverables.
Sr. Director PV Ops – Pharmacovigilance Center of Excellence
US-based biotech
